Morphologic parameters affect anti-VEGF therapy outcome

Article

Patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy to treat neovascular age-related macular degeneration (AMD) exhibit a distinct response pattern and time course of certain retinal morphologic changes.

Patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy to treat neovascular age-related macular degeneration (AMD) exhibit a distinct response pattern and time course of certain retinal morphologic changes. Some of the changes, such as intraretinal cysts, subretinal fluid and pigment epithelial detachments, can affect the patients' potential for visual gain.

Those were the findings of a study conducted by Researchers at Vienna Reading Center, Department of Ophthalmology, and the Institute of Environmental Health, Center for Public Health, Medical University of Vienna, Austria. The researchers conducted a subanalysis of the EXCITE (Efficacy and Safety of Ranibizumab in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration) phase IIIb clinical trial.

The researchers studied 353 treatment-naïve patients with subfoveal choroidal neovascularization. The patients were randomized to receive either quarterly (0.3 mg or 0.5 mg) or monthly (0.3 mg) doses of ranibizumab. The duration of treatment was 12 months: a loading phase consisting of 3 consecutive monthly injections, then 9 months of either the monthly or quarterly injections.

The researchers identified a significant correlation between a reduction in central retinal thickness and an increase in best-corrected visual acuity (as measured using the Early Treatment Diabetic Retinopathy Study protocol) (P

Retinal morphology was assessed by time-domain optical coherence tomography, and the researchers found that the proportion of patients showing changes decreased significantly in all three treatment groups (P

In terms of visual acuity, the baseline presence of intraretinal cysts resulted in lower best-corrected visual acuity over the study period; recurrence during the study had no additional negative effect. Baseline presence of subretinal fluid did not affect visual recovery, but patients who had a recurrence during follow up tended to display an additional negative effect on function (P = 0.06). Pigment epithelial detachments had a negative effect on visual outcome only when they occurred in combination with subretinal fluid or intraretinal cysts.

The study was published online in Ophthalmology.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
© 2025 MJH Life Sciences

All rights reserved.